# EDGAR Filing Document

**Accession Number:** 0001466301
**File Stem:** 0001193125-23-032941
**Filing Date:** 2023-2
**Character Count:** 82322
**Document Hash:** 050bd262b28012a849c1181f438a98eb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-032941.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001193125-23-032941

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 78

**CONFORMED PERIOD OF REPORT**: 20230209

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clovis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001466301
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 900475355
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35347
- **FILM NUMBER:** 23613752

**BUSINESS ADDRESS:**
- **STREET 1:** 5500 FLATIRON PARKWAY
- **STREET 2:** SUITE 100
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** (303) 625-5000

**MAIL ADDRESS:**
- **STREET 1:** 5500 FLATIRON PARKWAY
- **STREET 2:** SUITE 100
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 OR 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of Earliest Event Reported): February 9, 2023

------

## Clovis Oncology, Inc.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35347** | **90-0475355** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **5500 Flatiron Parkway, Suite 100<br>Boulder, Colorado** | **80301** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (303) 625-5000

#### Not Applicable

#### (Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **symbol(s)<sup>(1)</sup>** | **Name of each exchange**<br> **on which registered** |
| Common Stock par Value $0.001 per Share | CLVSQ | N/A |

---

<sup>(1)</sup> On December 21, 2022, our common stock was suspended from trading on the NASDAQ Global Select Market ("<u>NASDAQ</u>"). On December 21, 2022, our common stock began trading on the OTC Pink Marketplace maintained by the OTC Markets Group, Inc. under the symbol "CLVSQ." On December 29, 2022, NASDAQ filed a Form 25 delisting our common stock from trading on NASDAQ, which delisting became effective at the opening of the trading session on January 9, 2023. In accordance with Rule 12d2-2 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), the de-registration of our common stock under Section 12(b) of the Exchange Act will become effective 90 days from the date of the Form 25 filing.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

------

#### Item 7.01 Regulation FD Disclosure.
As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the "<u>Company</u>") and certain of its subsidiaries (such subsidiaries being Clovis Oncology Ireland Limited ("<u>Clovis Ireland</u>") and Clovis Oncology UK Limited ("<u>Clovis UK</u>") filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the "<u>Court</u>" and such cases, the "<u>Cases</u>").

On February 9, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the "<u>Monthly Operating Reports</u>"), with the Court for the reporting month ended December 31, 2022, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference.

The Company expects to file future Monthly Operating Reports and other documents with the Court while the Cases remain pending. The filing of such reports and other documents may not be accompanied by a Form 8-K filing. The reports and other documents will also be available for review free of charge at https://cases.ra.kroll.com/Clovis/. Investors should review this website for additional information regarding the Company and the Cases.

------

#### Cautionary Note Regarding the Monthly Operating Reports
The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Reports, which were not prepared for the purpose of providing the basis for an investment decision relating to the Company's securities. The Monthly Operating Reports are limited in scope and have been prepared solely for the purpose of complying with requirements of the Court. The Monthly Operating Reports were not reviewed by independent accountants, are in a format prescribed by applicable bankruptcy laws, and are subject to future adjustment. The financial information in the Monthly Operating Reports are not prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and, therefore, may exclude items required by GAAP, such as certain reclassifications, eliminations, accruals, valuations and disclosures. The Monthly Operating Reports also relate to periods that are different from the historical periods required in the Company's reports pursuant to the Securities Act of 1933, as amended, or the Exchange Act.

#### Limitation on Incorporation by Reference
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 is being furnished for informational purposes only and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this current report (including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 attached hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

In connection with the Cases, the Debtors have obtained customary relief from the Court to transition into Chapter 11 without material disruption to their operations, including paying employee wages and benefits, maintaining relationships with vendors and suppliers in order to continue to supply Rubraca to patients, continuing its cash management system in the ordinary course of business, manage ongoing clinical trials and maintain regulatory approvals.

The Debtors have obtained $45 million of new money "debtor-in possession" (DIP) financing and the consensual use of cash collateral, proceeds of which, subject to the DIP Budget and certain other financing and operating covenants set forth in the DIP Credit Agreement and the DIP Order, may be used by the Debtors for their working capital needs, including maintaining their operations and funding the costs of the administration of the Cases.

The commencement of the Cases has not had a material impact on the Company's ongoing sponsored clinical trials; however, marketing and promotion of Rubraca have been significantly curtailed as a result of more limited resources within the DIP Budget and continuing management of expenses, including the termination of a significant portion of the Company's commercial sales organization in the US and almost entirely in Europe, which has and will continue to impact revenues. As of February 9, 2023, the Company has 140 employees. In order to continue to compensate and incentivize employees to implement the Company's strategy in bankruptcy for the benefit of stakeholders, including running a successful sales process and a transition of the Company's businesses to interested purchasers, with the approval of the Court, the Company has implemented a Key Employee Retention Program (KERP) for certain non-insiders and will seek Court approval to implement a Key Employee Incentive Plan (KEIP) for certain insiders, including the Company's executive management team.

The regulatory landscape for Rubraca remains uncertain. The Company's prior submission of an sNDA to the FDA and a Type II variation to EMA for a first-line maintenance treatment indication of Rubraca for women with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy are still pending. The sNDA was accepted for a standard review with a PDUFA date of June 25, 2023. The Day-74 letter from the FDA, which notifies an applicant of issues identified during the filing review phase and was received by the Company on November 4, 2022, reiterated that the submitted OS data from the ATHENA-MONO trial are immature and expressed the view that the current trends of certain OS HR estimates indicate that there may be potential harm for patients in certain sub-groups. The OS data submitted in the sNDA were immature at 15.8% (HRD) and 24.7% (ITT) with no statistically significant differences between rucaparib and control. The Company's current estimates suggest the OS data may reach 50% maturity in the first quarter of 2024 and 70% maturity in the fourth quarter of 2026. Based on

------

standard review timelines, FDA may have held its internal Mid-Cycle Meeting for the pending sNDA, and the Company awaits receipt of the Mid-Cycle Communication, which would be expected to provide an update on the review status of the application. Additionally, as previously disclosed, the Company concluded discussions with the FDA on a revised label to limit Rubraca's use in the second-line ovarian cancer maintenance indication to the tBRCA mutation patient population only, and the revised label was approved on December 21, 2022. With respect to the Type II variation submitted to EMA, the Company received the assessment report including requests for supplementary information on December 15, 2022. Although the report stated that the benefits of rucaparib in the claimed indication could be considered meaningful with a manageable safety profile, it also stated that there are still some uncertainties that need to be resolved before a positive recommendation could be made. The report described the lack of mature OS data as the main limitation and contains a number of requests for supplementary information. As is often the case at this stage of an assessment procedure, the report stated that the overall benefit/risk of Rubraca in the front line maintenance setting is currently negative. The Company expects to provide the requested supplementary information to EMA in March 2023.

The Company is seeking to sell its assets through a court supervised sales process in the Cases. On December 11, 2022, the Company entered into a "stalking horse" purchase and assignment agreement with Novartis Innovative Therapies AG ("<u>Novartis</u>") to sell substantially all of its rights to its pipeline targeted radionuclide therapy clinical development program, FAP-2286, including the Company's in-licensing agreement with 3B Pharmaceuticals GmbH. The transaction is part of a sale process under Section 363 of title 11 of the United States Code (the "<u>Bankruptcy Code</u>") that is subject to approval by the Court and compliance with agreed upon and Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions. In accordance with the sale process under Section 363 of the Bankruptcy Code, notice of the proposed sale to Novartis has been given to third parties and competing bids are being solicited. The deadline to submit competing bids for the FAP-2286 assets has been set for March 7, 2023 by the Court in the bidding procedures order. The transaction is subject to a number of closing conditions, including among others, (i) the accuracy of representations and warranties of the parties; (ii) the entry into a transition services agreement mutually acceptable to the parties; (iii) material compliance with the obligations of the parties set forth in the purchase agreement, including achievement of certain milestones by the Company related to the Cases and the sales process on a timely basis; (iv) no Material Adverse Effect (as defined in the purchase agreement) having occurred to the transferred assets; and (v) payment of cure costs in respect of any assigned contract related to the FAP-2286 assets.

Separately, the Company is also actively engaged in discussions with a number of interested parties with respect to a potential sale of its Rubraca assets and business. That sale would also be subject to review and approval by the Court and compliance with Court-approved bidding procedures. The deadline to submit bids for the purchase of the Company's Rubraca assets and business has been set for March 21, 2023 by the Court in the bidding procedures order. The Company will manage the bidding process and evaluate the bids, in consultation with its advisors and other primary constituents and as overseen by the Court. There can be no assurances that any qualified or acceptable bids will be received or, even if received, the Company will be able to agree upon definitive terms with any such bidders and, even if a definitive agreement is entered into, there can be no assurances that it would be approved by the Court or that it would ultimately be consummated.

In connection with the sale process, the Debtors have filed notices with the Court (and have delivered notices to counterparties to the Debtors' contracts) detailing the Debtors' estimated amounts necessary to cure any defaults under the Company's executory contracts and unexpired leases that could potentially be assumed and assigned to the purchasers of the FAP-2286 and/or Rubraca assets.

#### Cautionary Statements Regarding Trading in the Company's Securities
The Company's securityholders are cautioned that trading in the Company's securities during the pendency of the Cases is highly speculative and poses substantial risks. Trading prices for the Company's securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Cases. The Company cannot be certain that holders of the Company's common stock will receive any payment or other distribution on account of those shares in the Cases given the expected sales proceeds (including the highly contingent nature of certain later milestone payments) and the amount of the Debtors' liabilities to more senior creditors. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

------

#### Cautionary Note Regarding Forward-Looking Statements
This Form 8-K includes statements that are, or may be deemed, "forward-looking statements." In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein. Any forward-looking statements that we make in this Form 8-K speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 8-K or to reflect the occurrence of unanticipated events. The Company's forward-looking statements in this Form 8-K include, but are not limited to, statements about the Company's plans to sell its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code and the timing of such sales and ability to satisfy closing conditions; the Company's intention to continue operations during the Chapter 11 case; the Company's belief that the sale process will be in the best interest of the Company and its stakeholders; and other statements regarding the Company's strategy and future operations, performance and prospects among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Chapter 11 filings on the Company's liquidity and results of operations; changes in the Company's ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations; the outcome and timing of the Chapter 11 process and any potential asset sale; the effect of the Chapter 11 filings and any potential asset sale on the Company's relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the potential asset sale; uncertainty regarding obtaining Court approval of a sale of the Company's assets or other conditions to the potential asset sale; and the timing or amount of any distributions, if any, to the Company's stakeholders.

------

**Item 9.01. Financial Statements and Exhibits.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits:

---

| | |
|:---|:---|
| Exhibit | Description |
| 99.1 | [Clovis Oncology, Inc., Monthly Operating Report, dated December 31, 2022.](d400299dex991.htm) |
| 99.2 | [Clovis Oncology Ireland Limited, Monthly Operating Report, dated December 31, 2022.](d400299dex992.htm) |
| 99.3 | [Clovis Oncology UK Limited, Monthly Operating Report, dated December 31, 2022.](d400299dex993.htm) |
| 104 | The cover page from Clovis Oncology, Inc.'s Current Report on Form 8-K is formatted in iXBRL. |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 10, 2023 |  |  |
|  | **CLOVIS ONCOLOGY, INC.** | **CLOVIS ONCOLOGY, INC.** |
|  | By: | /s/ Paul Gross |
|  |  | Name: Paul Gross |
|  |  | Title: Executive Vice President and General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g4002999.jpg)

UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 12/31/2022 Petition Date: 12/11/2022 Months Pending: 1 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 119 Debtor's Full-Time Employees (as of date of order for relief): 120 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Andrew S. Mordkoff Andrew S. Mordkoff Signature of Responsible Party Printed Name of Responsible Party 02/08/2023 Date 787 Seventh Avenue, New York, New York 10019-6099 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies. UST Form 11-MOR (12/01/2021) 1

------

![LOGO](g40029910.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 a. Cash balance beginning of month $7,157,147 b. Total receipts (net of transfers between accounts) $32,842,049 $32,842,049 c. Total disbursements (net of transfers between accounts) $1,392,300 $1,392,300 d. Cash balance end of month (a+b-c) $38,606,896 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $1,392,300 $1,392,300 a. Accounts receivable (total net of allowance) $12,621,898 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory (Book Market Other (attach explanation)) $96,207,143 d Total current assets $184,984,565 e. Total assets $314,981,798 f. Postpetition payables (excluding taxes) $39,967,803 g. Postpetition payables past due (excluding taxes) $627,827 h. Postpetition taxes payable $0 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $39,967,803 k. Prepetition secured debt $346,993,967 l. Prepetition priority debt $40,600 m. Prepetition unsecured debt $498,564,016 n. Total liabilities (debt) (j+k+l+m) $885,566,386 o. Ending equity/net worth (e-n) $-570,584,588 a. Total cash sales price for assets sold/transferred outside the ordinary $0 $0 course of business b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 a. Gross income/sales (net of returns and allowances) $7,446,976 b. Cost of goods sold (inclusive of depreciation, if applicable) $2,148,027 c. Gross profit (a-b) $5,298,949 d. Selling expenses $-208,763 e. General and administrative expenses $11,669,979 f. Other expenses $647,299 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $120,268,051 i. Taxes (local, state, and federal) $72,018 j. Reorganization items $80,259 k. Profit (loss) $-133,461,703 $-133,461,703 UST Form 11-MOR (12/01/2021) 2

------

![LOGO](g40029911.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi UST Form 11-MOR (12/01/2021) 3

------

![LOGO](g40029912.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii UST Form 11-MOR (12/01/2021) 4

------

![LOGO](g40029913.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv UST Form 11-MOR (12/01/2021) 5

------

![LOGO](g40029914.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi UST Form 11-MOR (12/01/2021) 6

------

![LOGO](g40029915.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii UST Form 11-MOR (12/01/2021) 7

------

![LOGO](g40029916.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 xcix c c. All professional fees and expenses (debtor & committees) $0 $0 $0 $0 a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $0 $0 d. Postpetition employer payroll taxes paid $0 $0 e. Postpetition property taxes paid $0 $0 f. Postpetition other taxes accrued (local, state, and federal) $0 $0 g. Postpetition other taxes paid (local, state, and federal) $0 $0 a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930? UST Form 11-MOR (12/01/2021) 8

------

![LOGO](g40029917.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Daniel W. Muehl Daniel W. Muehl Signature of Responsible Party Printed Name of Responsible Party Executive Vice President and Chief Financial Officer 02/08/2023 Title Date UST Form 11-MOR (12/01/2021) 9

------

![LOGO](g40029918.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo UST Form 11-MOR (12/01/2021) 10

------

![LOGO](g40029919.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100 UST Form 11-MOR (12/01/2021) 11

------

![LOGO](g40029920.jpg)

Debtor's Name Clovis Oncology, Inc. Case No. 22-11292 PageThree PageFour UST Form 11-MOR (12/01/2021) 12

------

![LOGO](g40029921.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Cash Receipts and Disbursements Reporting Period: Dec 11—Dec 31, 2022 Debtor Third-Party Cash Disbursements Clovis Oncology, Inc. 1,392,300 Clovis Oncology UK Limited 86,398 Clovis Oncology Ireland Limited 23,752 Total 1,502,450 Debtor Third-Party Cash Receipts Clovis Oncology, Inc. 32,739,902 Clovis Oncology UK Limited 25,957 Clovis Oncology Ireland Limited - Total 32,765,860 #AlixPartners General

------

![LOGO](g40029922.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Bank Account Information Reporting Period: Dec 11—Dec 31, 2022 Debtor Bank Last 4 Digits Description Balance as of Month End (USD) Clovis Oncology, Inc. JP Morgan 9101 Lockbox Account 4,838,538 Clovis Oncology, Inc. JP Morgan 8623 Operating Account 26,993,091 Clovis Oncology, Inc. JP Morgan 9601 Operating Account 34 Clovis Oncology, Inc. JP Morgan 9602 Operating Account 2,056 Clovis Oncology, Inc. JP Morgan 3424 Operating Account 687 Clovis Oncology, Inc. JP Morgan 8157 Investment Account 6,672,490 Clovis Oncology, Inc. JP Morgan 2038 Investment Account 100,000 Clovis Oncology UK Limited JP Morgan 4225 Lockbox Account 2,984,136 Clovis Oncology UK Limited JP Morgan 2330 Operating Account 4,903,362 Clovis Oncology Ireland Limited JP Morgan 0565 Lockbox Account 68,626 Clovis Oncology Ireland Limited JP Morgan 1185 Operating Account 553,332 Sub Total—Bank Accounts 47,116,352 Total 47,116,352 #AlixPartners General

------

![LOGO](g40029923.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Balance Sheet as of December 31, 2022 Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Assets Current Assets: Cash and Cash Equivalents 38,606,897 7,887,498 621,957 Trade Accounts Receivable, Net 12,621,898 5,802,510 4,609 Interco Receivables 21,953,479 551 7,283,042 Pre-Petition—Inter Company Debtor Receivables Inventories 96,207,143 — 13,247,702 Prepayments and Deposits 15,582,729 14,793 12,950 Other Assets—Current 12,417 2,735,563 26,392 IC Investment in Subsidiaries 2 229,143 - Total Current Assets 184,984,565 16,670,057 21,196,653 Non-Current Assets: Property, Plant and Equipment, Net 481,414 136,605 -Goodwill 63,074,218 — -Other Intangible Assets, Net 55,000,286 — -Other Assets—Non-current 11,441,315 262,827 34,195 Total Non-Current Assets 129,997,233 399,433 34,195 Total Assets 314,981,798 17,069,489 21,230,848 Liabilities Current Liabilities: DIP Financing 30,000,000 — -Trade Accounts Payable, Net 1,331,976 76,940 34,005 Interco Payables (409,039) 754,943 18,362,246 Misc. Liabilities & Accrued Expenses 8,931,561 4,164,577 109,788 Accrued Taxes (Income, Payroll, etc.) (17,614) 1,897,591 277,806 Lease Liability—Short-term 130,920 202,777 16,965 Other Notes Payable—Current — — - Total Current Liabilities 39,967,803 7,096,829 18,800,809 Non-Current Liabilities Lease Liability—Long-term 0 0 15,019 Total Non-Current Liabilities 0 0 15,019 Liabilities Subject to Compromise 845,598,583 7,294,983 74,315 Total Liabilities 885,566,386 14,391,812 18,890,144 Equity Common Stock 145,068 2 141 Additional Paid in Capital 2,691,517,358 — -Accumulated Other Comprehensive Loss (41,905,090) (459,281) 86,265 Accumulated Deficit (3,220,341,925) 3,136,957 2,254,299 Total Equity (570,584,588) 2,677,677 2,340,704 Total Liabilities and Equity 314,981,798 17,069,489 21,230,848 Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change. #AlixPartners General

------

![LOGO](g40029924.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Statement of Operations for the month of December 2022 Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Total Revenue 7,446,976 445,325 1,916,352 Operating Expenses: Cost of Goods Sold 804,825 565,937 1,057,856 Royalty Expense 1,343,202 — -Research and Development 3,632,718 — -General and Administrative 11,669,979 586,405 13,875 Selling Expenses (208,763) 66,291 -Operating Taxes 72,018 — -Other Operating Expenses 514,810 — - Total Operating Expenses 17,828,790 1,218,633 1,071,732 Total Operating Profit (Loss) (10,381,814) (773,308) 844,620 Other Income and Expenses: Interest Income 37,853 — -Gain/Loss from Sale of Assets (3,153,757) (770,843) -Interest Expense 120,230,198 1,861 11,935 Foreign Currency Translation Adjustments (379,321) 36,970 (275,635) Gain/Loss on Available-For-Sale Securities 32,848 — -Reorganization Costs 80,259 (113,255) -Income Tax Expense — (251,313) 397,526 Net Other Income (123,079,889) (445,106) (133,825) Net Income (133,461,703) (1,218,414) 710,795 Notes: 1) The activity reported above represents the full month of December. 2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future. #AlixPartners General

------

![LOGO](g40029925.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Accounts Receivable Reconciliation and Aging Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology, Inc. Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 12,801,690 330,030 —— 13,131,720 Less: Prompt Pay Discounts & Returns (492,373) — — — (492,373) Less: Allowance for Bad Debts (15,799) (1,650) — — (17,449) Net Accounts Receivable 12,293,518 328,380 —— 12,621,898 Clovis Oncology UK Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 5,819,970 — — — 5,819,970 Less: Allowance for Bad Debts (17,460) — — — (17,460) Net Accounts Receivable 5,802,510 — — — 5,802,510 Clovis Oncology Ireland Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 4,632 — —— 4,632 Less: Allowance for Bad Debts (23) — — — (23) Net Accounts Receivable 4,609 — — — 4,609 AlixPartners General

------

![LOGO](g40029926.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Post-Petition Accounts Payable Aging Reporting Period: Dec 11—Dec 31, 2022 Debtor Total Current 0-30 Days 31-60 Days 61-90 Days 91+ Days Clovis Oncology, Inc. 1,332,293 704,466 353,408 24,587 7,163 242,669 Clovis Oncology UK Limited 76,940 45,240 31,728 (28) — - Clovis Oncology Ireland Limited 34,005 34,005 — — — - Net Accounts Payable 1,443,238 783,711 385,136 24,559 7,163 242,669 Notes: 1) While the Debtors' AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case. #AlixPartners General

------

![LOGO](g40029927.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Capital Assets Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Net Book Value Computer Equipment 159,402 107,204 -Furniture and Fixtures 246,621 4,267 -Lab Equipment 5,460 -Leasehold Improvements 47,600 — -Licensed Software — -Manufacturing Equipment 5,512 -Office Equipment 9,929 1,389 -Trade Booth — — - Net Book Value 474,524 112,859 - #AlixPartners General

------

![LOGO](g40029928.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Payments to Insiders Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Payments to Insiders 145,763—— The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of December 11 through December 31, 2022. With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period. /s/ Daniel W. Muehl 02/08/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual Notes: 1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors' Statements of Financial Affairs. The amount listed Includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements. #AlixPartners General

------

![LOGO](g40029929.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Status of Post-Petition Taxes Reporting Period: Dec 11—Dec 31, 2022 The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute. /s/ Daniel W. Muehl 02/08/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual #AlixPartners General

## Exhibit 99.2

**Exhibit 99.2**![LOGO](g40029930.jpg)

UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 12/31/2022 Petition Date: 12/11/2022 Months Pending: 1 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 1 Debtor's Full-Time Employees (as of date of order for relief): 1 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Andrew S. Mordkoff Andrew S. Mordkoff Signature of Responsible Party Printed Name of Responsible Party 02/08/2023 Date 787 Seventh Avenue, New York, New York 10019-6099 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies. UST Form 11-MOR (12/01/2021) 1

------

![LOGO](g40029931.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 a. Cash balance beginning of month $631,500 b. Total receipts (net of transfers between accounts) $14,210 $14,210 c. Total disbursements (net of transfers between accounts) $23,752 $23,752 d. Cash balance end of month (a+b-c) $621,958 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $23,752 $23,752 a. Accounts receivable (total net of allowance) $4,609 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory (Book Market Other (attach explanation)) $13,247,702 d Total current assets $21,196,653 e. Total assets $21,230,848 f. Postpetition payables (excluding taxes) $18,815,829 g. Postpetition payables past due (excluding taxes) $0 h. Postpetition taxes payable $0 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $18,815,829 k. Prepetition secured debt $0 l. Prepetition priority debt $0 m. Prepetition unsecured debt $74,315 n. Total liabilities (debt) (j+k+l+m) $18,890,144 o. Ending equity/net worth (e-n) $2,340,704 a. Total cash sales price for assets sold/transferred outside the ordinary $0 $0 course of business b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 a. Gross income/sales (net of returns and allowances) $1,916,352 b. Cost of goods sold (inclusive of depreciation, if applicable) $1,057,856 c. Gross profit (a-b) $858,496 d. Selling expenses $0 e. General and administrative expenses $13,875 f. Other expenses $-275,635 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $11,935 i. Taxes (local, state, and federal) $397,526 j. Reorganization items $0 k. Profit (loss) $710,795 $710,795 UST Form 11-MOR (12/01/2021) 2

------

![LOGO](g40029932.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 Part 5: Professional Fees and Expenses Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi UST Form 11-MOR (12/01/2021) 3

------

![LOGO](g40029933.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii UST Form 11-MOR (12/01/2021) 4

------

![LOGO](g40029934.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv UST Form 11-MOR (12/01/2021) 5

------

![LOGO](g40029935.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi UST Form 11-MOR (12/01/2021) 6

------

![LOGO](g40029936.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii UST Form 11-MOR (12/01/2021) 7

------

![LOGO](g40029937.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 xcix c c. All professional fees and expenses (debtor & committees) $0 $0 $0 $0 a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $0 $0 d. Postpetition employer payroll taxes paid $0 $0 e. Postpetition property taxes paid $0 $0 f. Postpetition other taxes accrued (local, state, and federal) $0 $0 g. Postpetition other taxes paid (local, state, and federal) $0 $0 a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930? UST Form 11-MOR (12/01/2021) 8

------

![LOGO](g40029938.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Daniel W. Muehl Daniel W. Muehl Signature of Responsible Party Printed Name of Responsible Party Executive Vice President and Chief Financial Officer 02/08/2023 Title Date UST Form 11-MOR (12/01/2021) 9

------

![LOGO](g40029939.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo UST Form 11-MOR (12/01/2021) 10

------

![LOGO](g40029940.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100 UST Form 11-MOR (12/01/2021) 11

------

![LOGO](g40029941.jpg)

Debtor's Name Clovis Oncology Ireland Limited Case No. 22-11294 PageThree PageFour UST Form 11-MOR (12/01/2021) 12

------

![LOGO](g40029942.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Cash Receipts and Disbursements Reporting Period: Dec 11—Dec 31, 2022 Debtor Third-Party Cash Disbursements Clovis Oncology, Inc. 1,392,300 Clovis Oncology UK Limited 86,398 Clovis Oncology Ireland Limited 23,752 Total 1,502,450 Debtor Third-Party Cash Receipts Clovis Oncology, Inc. 32,739,902 Clovis Oncology UK Limited 25,957 Clovis Oncology Ireland Limited - Total 32,765,860 #AlixPartners General

------

![LOGO](g40029943.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Bank Account Information Reporting Period: Dec 11—Dec 31, 2022 Debtor Bank Last 4 Digits Description Balance as of Month End (USD) Clovis Oncology, Inc. JP Morgan 9101 Lockbox Account 4,838,538 Clovis Oncology, Inc. JP Morgan 8623 Operating Account 26,993,091 Clovis Oncology, Inc. JP Morgan 9601 Operating Account 34 Clovis Oncology, Inc. JP Morgan 9602 Operating Account 2,056 Clovis Oncology, Inc. JP Morgan 3424 Operating Account 687 Clovis Oncology, Inc. JP Morgan 8157 Investment Account 6,672,490 Clovis Oncology, Inc. JP Morgan 2038 Investment Account 100,000 Clovis Oncology UK Limited JP Morgan 4225 Lockbox Account 2,984,136 Clovis Oncology UK Limited JP Morgan 2330 Operating Account 4,903,362 Clovis Oncology Ireland Limited JP Morgan 0565 Lockbox Account 68,626 Clovis Oncology Ireland Limited JP Morgan 1185 Operating Account 553,332 Sub Total—Bank Accounts 47,116,352 Total 47,116,352 AlixPartners General

------

![LOGO](g40029944.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Balance Sheet as of December 31, 2022 Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Assets Current Assets: Cash and Cash Equivalents 38,606,897 7,887,498 621,957 Trade Accounts Receivable, Net 12,621,898 5,802,510 4,609 Interco Receivables 21,953,479 551 7,283,042 Pre-Petition—Inter Company Debtor Receivables Inventories 96,207,143 — 13,247,702 Prepayments and Deposits 15,582,729 14,793 12,950 Other Assets—Current 12,417 2,735,563 26,392 IC Investment in Subsidiaries 2 229,143 - Total Current Assets 184,984,565 16,670,057 21,196,653 Non-Current Assets: Property, Plant and Equipment, Net 481,414 136,605 -Goodwill 63,074,218 — -Other Intangible Assets, Net 55,000,286 — -Other Assets—Non-current 11,441,315 262,827 34,195 Total Non-Current Assets 129,997,233 399,433 34,195 Total Assets 314,981,798 17,069,489 21,230,848 Liabilities Current Liabilities: DIP Financing 30,000,000 — -Trade Accounts Payable, Net 1,331,976 76,940 34,005 Interco Payables (409,039) 754,943 18,362,246 Misc. Liabilities & Accrued Expenses 8,931,561 4,164,577 109,788 Accrued Taxes (Income, Payroll, etc.) (17,614) 1,897,591 277,806 Lease Liability—Short-term 130,920 202,777 16,965 Other Notes Payable—Current — — - Total Current Liabilities 39,967,803 7,096,829 18,800,809 Non-Current Liabilities Lease Liability—Long-term 0 0 15,019 Total Non-Current Liabilities 0 0 15,019 Liabilities Subject to Compromise 845,598,583 7,294,983 74,315 Total Liabilities 885,566,386 14,391,812 18,890,144 Equity Common Stock 145,068 2 141 Additional Paid in Capital 2,691,517,358 — -Accumulated Other Comprehensive Loss (41,905,090) (459,281) 86,265 Accumulated Deficit (3,220,341,925) 3,136,957 2,254,299 Total Equity (570,584,588) 2,677,677 2,340,704 Total Liabilities and Equity 314,981,798 17,069,489 21,230,848 Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change. ##AlixPartners General

------

![LOGO](g40029945.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Statement of Operations for the month of December 2022 Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Total Revenue 7,446,976 445,325 1,916,352 Operating Expenses: Cost of Goods Sold 804,825 565,937 1,057,856 Royalty Expense 1,343,202 — -Research and Development 3,632,718 — -General and Administrative 11,669,979 586,405 13,875 Selling Expenses (208,763) 66,291 -Operating Taxes 72,018 — -Other Operating Expenses 514,810 — - Total Operating Expenses 17,828,790 1,218,633 1,071,732 Total Operating Profit (Loss) (10,381,814) (773,308) 844,620 Other Income and Expenses: Interest Income 37,853 — -Gain/Loss from Sale of Assets (3,153,757) (770,843) -Interest Expense 120,230,198 1,861 11,935 Foreign Currency Translation Adjustments (379,321) 36,970 (275,635) Gain/Loss on Available-For-Sale Securities 32,848 — -Reorganization Costs 80,259 (113,255) -Income Tax Expense — (251,313) 397,526 Net Other Income (123,079,889) (445,106) (133,825) Net Income (133,461,703) (1,218,414) 710,795 Notes: 1) The activity reported above represents the full month of December. 2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future. #AlixPartners General

------

![LOGO](g40029946.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Accounts Receivable Reconciliation and Aging Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology, Inc. Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 12,801,690 330,030 — — 13,131,720 Less: Prompt Pay Discounts & Returns (492,373) — — — (492,373) Less: Allowance for Bad Debts (15,799) (1,650) — — (17,449) Net Accounts Receivable 12,293,518 328,380 — — 12,621,898 Clovis Oncology UK Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 5,819,970 — — — 5,819,970 Less: Allowance for Bad Debts (17,460) — — — (17,460) Net Accounts Receivable 5,802,510 — — — 5,802,510 Clovis Oncology Ireland Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 4,632 — — — 4,632Less: Allowance for Bad Debts (23) — — — (23) Net Accounts Receivable 4,609 — — — 4,609 AlixPartners General

------

![LOGO](g40029947.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Post-Petition Accounts Payable Aging Reporting Period: Dec 11—Dec 31, 2022 Debtor Total Current 0-30 Days 31-60 Days 61-90 Days 91+ Days Clovis Oncology, Inc. 1,332,293 704,466 353,408 24,587 7,163 242,669 Clovis Oncology UK Limited 76,940 45,240 31,728 (28) — -Clovis Oncology Ireland Limited 34,005 34,005 — — — - Net Accounts Payable 1,443,238 783,711 385,136 24,559 7,163 242,669 Notes: 1) While the Debtors' AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case. ##AlixPartners General

------

![LOGO](g40029948.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Capital Assets Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Net Book Value Computer Equipment 159,402 107,204 -Furniture and Fixtures 246,621 4,267 -Lab Equipment 5,460 -Leasehold Improvements 47,600 — -Licensed Software — -Manufacturing Equipment 5,512 -Office Equipment 9,929 1,389 -Trade Booth — — - Net Book Value 474,524 112,859 - #AlixPartners General

------

![LOGO](g40029949.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Payments to Insiders Reporting Period: Dec 11—Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Payments to Insiders 145,763—— The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of December 11 through December 31, 2022. With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period. /s/ Daniel W. Muehl 02/08/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual Notes: 1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors' Statements of Financial Affairs. The amount listed Includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements. #AlixPartners General

------

![LOGO](g40029950.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Status of Post-Petition Taxes Reporting Period: Dec 11—Dec 31, 2022 The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute. /s/ Daniel W. Muehl 02/08/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual #AlixPartners General

## Exhibit 99.3

**Exhibit 99.3**![LOGO](g40029951.jpg)

UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 12/31/2022 Petition Date: 12/11/2022 Months Pending: 1 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 49 Debtor's Full-Time Employees (as of date of order for relief): 49 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Andrew S. Mordkoff Andrew S. Mordkoff Signature of Responsible Party Printed Name of Responsible Party 02/08/2023 Date 787 Seventh Avenue, New York, New York 10019-6099 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies. UST Form 11-MOR (12/01/2021) 1

------

![LOGO](g40029952.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 a. Cash balance beginning of month $8,077,306 b. Total receipts (net of transfers between accounts) $-103,410 $-103,410 c. Total disbursements (net of transfers between accounts) $86,398 $86,398 d. Cash balance end of month (a+b-c) $7,887,498 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $86,398 $86,398 a. Accounts receivable (total net of allowance) $5,802,510 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory (Book Market Other (attach explanation)) $0 d Total current assets $16,670,057 e. Total assets $17,069,489 f. Postpetition payables (excluding taxes) $7,096,829 g. Postpetition payables past due (excluding taxes) $31,700 h. Postpetition taxes payable $0 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $7,096,829 k. Prepetition secured debt $0 l. Prepetition priority debt $0 m. Prepetition unsecured debt $7,294,983 n. Total liabilities (debt) (j+k+l+m) $14,391,812 o. Ending equity/net worth (e-n) $2,677,677 a. Total cash sales price for assets sold/transferred outside the ordinary $0 $0 course of business b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 a. Gross income/sales (net of returns and allowances) $445,325 b. Cost of goods sold (inclusive of depreciation, if applicable) $565,937 c. Gross profit (a-b) $-120,612 d. Selling expenses $66,291 e. General and administrative expenses $586,405 f. Other expenses $-733,873 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $1,861 i. Taxes (local, state, and federal) $-251,313 j. Reorganization items $-113,255 k. Profit (loss) $-1,218,414 $-1,218,414 UST Form 11-MOR (12/01/2021) 2

------

![LOGO](g40029953.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtor's professional fees & expenses (bankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi UST Form 11-MOR (12/01/2021) 3

------

![LOGO](g40029954.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii UST Form 11-MOR (12/01/2021) 4

------

![LOGO](g40029955.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv UST Form 11-MOR (12/01/2021) 5

------

![LOGO](g40029956.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi UST Form 11-MOR (12/01/2021) 6

------

![LOGO](g40029957.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii UST Form 11-MOR (12/01/2021) 7

------

![LOGO](g40029958.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 xcix c c. All professional fees and expenses (debtor & committees) $0 $0 $0 $0 a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $0 $0 d. Postpetition employer payroll taxes paid $0 $0 e. Postpetition property taxes paid $0 $0 f. Postpetition other taxes accrued (local, state, and federal) $0 $0 g. Postpetition other taxes paid (local, state, and federal) $0 $0 a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Worker's compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930? UST Form 11-MOR (12/01/2021) 8

------

![LOGO](g40029959.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Daniel W. Muehl Daniel W. Muehl Signature of Responsible Party Printed Name of Responsible Party Executive Vice President and Chief Financial Officer 02/08/2023 Title Date UST Form 11-MOR (12/01/2021) 9

------

![LOGO](g40029960.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo UST Form 11-MOR (12/01/2021) 10

------

![LOGO](g40029961.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100 UST Form 11-MOR (12/01/2021) 11

------

![LOGO](g40029962.jpg)

Debtor's Name Clovis Oncology UK Limited Case No. 22-11293 PageThree PageFour UST Form 11-MOR (12/01/2021) 12

------

![LOGO](g40029963.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Cash Receipts and Disbursements Reporting Period: Dec 11 - Dec 31, 2022 Debtor Third-Party Cash Disbursements Clovis Oncology, Inc. 1,392,300 Clovis Oncology UK Limited 86,398 Clovis Oncology Ireland Limited 23,752 Total 1,502,450 Debtor Third-Party Cash Receipts Clovis Oncology, Inc. 32,739,902 Clovis Oncology UK Limited 25,957 Clovis Oncology Ireland Limited - Total 32,765,860 #AlixPartners General

------

![LOGO](g40029964.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Bank Account Information Reporting Period: Dec 11 - Dec 31, 2022 Debtor Bank Last 4 Digits Description Balance as of Month End (USD) Clovis Oncology, Inc. JP Morgan 9101 Lockbox Account 4,838,538 Clovis Oncology, Inc. JP Morgan 8623 Operating Account 26,993,091 Clovis Oncology, Inc. JP Morgan 9601 Operating Account 34 Clovis Oncology, Inc. JP Morgan 9602 Operating Account 2,056 Clovis Oncology, Inc. JP Morgan 3424 Operating Account 687 Clovis Oncology, Inc. JP Morgan 8157 Investment Account 6,672,490 Clovis Oncology, Inc. JP Morgan 2038 Investment Account 100,000 Clovis Oncology UK Limited JP Morgan 4225 Lockbox Account 2,984,136 Clovis Oncology UK Limited JP Morgan 2330 Operating Account 4,903,362 Clovis Oncology Ireland Limited JP Morgan 0565 Lockbox Account 68,626 Clovis Oncology Ireland Limited JP Morgan 1185 Operating Account 553,332 Sub Total - Bank Accounts 47,116,352 Total 47,116,352 #AlixPartners General

------

![LOGO](g40029965.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Balance Sheet as of December 31, 2022 Reporting Period: Dec 11-Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Assets Current Assets: Cash and Cash Equivalents 38,606,897 7,887,498 621,957 Trade Accounts Receivable, Net 12,621,898 5,802,510 4,609 Interco Receivables 21,953,479 551 7,283,042 Pre-Petition-Inter Company Debtor Receivables Inventories 96,207,143 - 13,247,702 Prepayments and Deposits 15,582,729 14,793 12,950 Other Assets-Current 12,417 2,735,563 26,392 IC Investment in Subsidiaries 2 229,143 - Total Current Assets 184,984,565 16,670,057 21,196,653 Non-Current Assets: Property, Plant and Equipment, Net 481,414 136,605 -Goodwill 63,074,218 - -Other Intangible Assets, Net 55,000,286 - -Other Assets-Non-current 11,441,315 262,827 34,195 Total Non-Current Assets 129,997,233 399,433 34,195 Total Assets 314,981,798 17,069,489 21,230,848 Liabilities Current Liabilities: DIP Financing 30,000,000 - -Trade Accounts Payable, Net 1,331,976 76,940 34,005 Interco Payables (409,039) 754,943 18,362,246 Misc. Liabilities & Accrued Expenses 8,931,561 4,164,577 109,788 Accrued Taxes (Income, Payroll, etc.) (17,614) 1,897,591 277,806 Lease Liability-Short-term 130,920 202,777 16,965 Other Notes Payable-Current - - - Total Current Liabilities 39,967,803 7,096,829 18,800,809 Non-Current Liabilities Lease Liability-Long-term 0 0 15,019 Total Non-Current Liabilities 0 0 15,019 Liabilities Subject to Compromise 845,598,583 7,294,983 74,315 Total Liabilities 885,566,386 14,391,812 18,890,144 Equity Common Stock 145,068 2 141 Additional Paid in Capital 2,691,517,358 - -Accumulated Other Comprehensive Loss (41,905,090) (459,281) 86,265 Accumulated Deficit (3,220,341,925) 3,136,957 2,254,299 Total Equity (570,584,588) 2,677,677 2,340,704 Total Liabilities and Equity 314,981,798 17,069,489 21,230,848 Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change. #AlixPartners General

------

![LOGO](g40029966.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Statement of Operations for the month of December 2022 Reporting Period: Dec 11 - Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Total Revenue 7,446,976 445,325 1,916,352 Operating Expenses: Cost of Goods Sold 804,825 565,937 1,057,856 Royalty Expense 1,343,202 - - Research and Development 3,632,718 - - General and Administrative 11,669,979 586,405 13,875 Selling Expenses (208,763) 66,291 - Operating Taxes 72,018 - -Other Operating Expenses 514,810 - - Total Operating Expenses 17,828,790 1,218,633 1,071,732 Total Operating Prof it (Loss) (10,381,814) (773,308) 844,620 Other Income and Expenses: Interest Income 37,853 - - Gain/Loss from Sale of Assets (3,153,757) (770,843) - Interest Expense 120,230,198 1,861 11,935 Foreign Currency Translation Adjustments (379,321) 36,970 (275,635) Gain/Loss on Available-For-Sale Securities 32,848 - - Reorganization Costs 80,259 (113,255) - Income Tax Expense - (251,313) 397,526 Net Other Income (123,079,889) (445,106) (133,825) Net Income (133,461,703) (1,218,414) 710,795 Notes: 1) The activity reported above represents the full month of December. 2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future. #AlixPartners General

------

![LOGO](g40029967.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Accounts Receivable Reconciliation and Aging Reporting Period: Dec 11-Dec 31, 2022 Clovis Oncology, Inc. Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 12,801,690 330,030 - - 13,131,720 Less: Prompt Pay Discounts & Returns (492,373) - - - (492,373) Less: Allowance for Bad Debts (15,799) (1,650) - - (17,449) Net Accounts Receivable 12,293,518 328,380 - - 12,621,898 Clovis Oncology UK Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 5,819,970 - - - 5,819,970 Less: Allowance for Bad Debts (17,460) - - - (17,460) Net Accounts Receivable 5,802,510 - - - 5,802,510 Clovis Oncology Ireland Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 4,632 - - - 4,632 Less: Allowance for Bad Debts (23) - - - (23) Net Accounts Receivable 4,609 - - - 4,609 AlixPartners General

------

![LOGO](g40029968.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Post-Petition Accounts Payable Aging Reporting Period: Dec 11- Dec 31, 2022 Debtor Total Current 0 - 30 Days 31-60 Days 61-90 Days 91+ Days Clovis Oncology, Inc. 1,332,293 704,466 353,408 24,587 7,163 242,669 Clovis Oncology UK Limited 76,940 45,240 31,728 (28) - - Clovis Oncology Ireland Limited 34,005 34,005 - - - - Net Accounts Payable 1,443,238 783,711 385,136 24,559 7,163 242,669 Notes: 1) While the Debtors' AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case. #AlixPartners General

------

![LOGO](g40029969.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Capital Assets Reporting Period: Dec 11-Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Net Book Value Computer Equipment 159,402 107,204 - Furniture and Fixtures 246,621 4,267 - Lab Equipment 5,460 - Leasehold Improvements 47,600 - -Licensed Software - - Manufacturing Equipment 5,512 - Office Equipment 9,929 1,389 - Trade Booth - - - Net Book Value 474,524 112,859 - #AlixPartners General

------

![LOGO](g40029970.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Payments to Insiders Reporting Period: Dec 11-Dec 31, 2022 Clovis Oncology UK Clovis Oncology Ireland USD Actuals Clovis Oncology, Inc. Limited Limited Payments to Insiders 145,763 - - The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of December 11 through December 31, 2022. With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period. /s/ Daniel W. Muehl 02/08/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual Notes: 1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors' Statements of Financial Affairs. The amount listed Includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements. #AlixPartners General

------

![LOGO](g40029971.jpg)

In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Status of Post-Petition Taxes Reporting Period: Dec 11 - Dec 31, 2022 The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute. /s/ Daniel W. Muehl 02/08/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual #AlixPartners General